For patients with androgenetic alopecia resistant to minoxidil or finasteride, or those unable to tolerate oral pharmacotherapy, exosome treatments offer a low-risk investigational route with modest efficacy data. Cost-benefit depends on expectation alignment (partial thickening rather than full reversal) and individual psychological burden of hair loss. Aesthetic outcomes are subjective; before-and-after image quality and clinic track record merit close review.
Androgenetic alopecia and other hair-loss conditions result from follicle miniaturisation, stem-cell exhaustion within the dermal papilla, and inflammatory signalling that disrupts the hair growth cycle. Exosomes derived from umbilical-cord fibroblasts and mesenchymal stem cells contain growth factors (bFGF, VEGF, HGF), microRNAs (miR-29b regulating collagen cross-linking), and lipid mediators that promote angiogenesis, collagen deposition, and hair-follicle neogenesis in preclinical models. Sixteen registered clinical trials and four actively recruiting studies assess topical, intradermal, and systemic exosome formulations alongside platelet-rich plasma and conventional minoxidil or finasteride regimens.
Sunt un candidat? → · Hair Loss & Restoration: full overview → · Cost Pierderea de Păr și Restaurarea Părului → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită